Treatment options for Penile cancer mapped across 5 countries — covering cell therapy, chemotherapy, clinical trials and immunotherapy — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedSolid tumorLast checked June 2026
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
Stimotimagene copolymerplasmid plus ganciclovirClinical trial · NCT05578820Clinical trialTrial only (registry)Russia · Phase 1 safety, tolerability, and pharmacokinetics investigation in multiple tumor types including penile neoplasms. · The trial is completed and broad across several cancers. The registry text does not state a penile-cancer-specific cohort result, standard-of-care role, or active availability. Confidence/conflicts: Medium-high for the existence of a Russia-site broad tumor-type registry cell including penile neoplasms; low for penile-specific treatment relevance beyond investigational context. No regulator approval claim is made. reimbursement not established in this jurisdiction trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
Pembrolizumab; platinum-based therapy plus pembrolizumab investigational contextClinical trialClinical trialInvestigationalMSI-H status may identify a responsive case in the fetched pembrolizumab case-series source; no broad biomarker claim made; Advanced penile SCC investigational systemic therapy context. · This is not a regulator approval, guideline recommendation, or availability claim. It should only be cataloged as an option to discuss in trial/biomarker context; no superiority or routine access implied. Confidence/conflicts: Medium; evidence is case-series/investigational and not a jurisdictional approval. Peer-reviewed literature / PMC — peer-reviewed case series
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
What is the stage, tumor location, and nodal/metastatic status?
Is the intent local control, organ preservation, palliation, or trial participation?
Are clinical trials available for stage III/IV or recurrent disease?
Is organ-preserving local treatment feasible for the tumor stage/location?